Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Quinapril Hydrochloride and Hydrochlorothiazide

×

Overview

What is Quinapril Hydrochloride and Hydrochlorothiazide?



What does Quinapril Hydrochloride and Hydrochlorothiazide look like?



What are the available doses of Quinapril Hydrochloride and Hydrochlorothiazide?

Sorry No records found.

What should I talk to my health care provider before I take Quinapril Hydrochloride and Hydrochlorothiazide?

Sorry No records found

How should I use Quinapril Hydrochloride and Hydrochlorothiazide?

DOSAGE AND ADMINISTRATION

WARNINGS: Neutropenia/Agranulocytosis

Angioedema in Black Patients:

WARNINGS

Therapy Guided by Clinical Effect

Replacement Therapy

Use in Renal Impairment

2


What interacts with Quinapril Hydrochloride and Hydrochlorothiazide?

Array


Array



What are the warnings of Quinapril Hydrochloride and Hydrochlorothiazide?

In 120 patients with hypertrophic cardiomyopathy (most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects were seen. Three patients died in pulmonary edema; all had severe left ventricular outflow obstruction and a past history of left ventricular dysfunction. Eight other patients had pulmonary edema and/or severe hypotension; abnormally high (over 20 mm Hg) capillary wedge pressure and a marked left ventricular outflow obstruction were present in most of these patients. Concomitant administration of quinidine (see ) preceded the severe hypotension in 3 of the 8 patients (2 of whom developed pulmonary edema). Sinus bradycardia occurred in 11% of the patients, second-degree AV block in 4% and sinus arrest in 2%. It must be appreciated that this group of patients had a serious disease with a high mortality rate. Most adverse effects responded well to dose reduction and only rarely did verapamil have to be discontinued.

Anaphylactoid and Possibly Related Reactions:

Intestinal Angioedema:

Anaphylactoid Reactions During Desensitization:

Anaphylactoid Reactions During Membrane Exposure:

Hepatic Failure:

Hypotension:

Impaired Renal Function:

Neutropenia/Agranulocytosis:

Fetal/Neonatal Morbidity and Mortality:

in utero

Impaired Hepatic Function:

Systemic Lupus Erythematosus:


What are the precautions of Quinapril Hydrochloride and Hydrochlorothiazide?

Derangements of Serum Electrolytes:

Array

Array

Array

Array

Array

Other Metabolic Disturbances:

Cough:

Surgery/Anesthesia:

Angioedema:

Pregnancy:

Symptomatic Hypotension:

Array

Array

Hyperkalemia:

Neutropenia:

NOTE:

Array

Array

Potassium Supplements and Potassium-Sparing Diuretics:

Lithium:

Tetracycline and Other Drugs That Interact with Magnesium:

Other Agents:

Array

Array

Array

in vitro

in vitro

in vivo

in vitro

Salmonella typhimurium

in vivo

Drosophila

in vitro

Aspergillus nidulans

Array

Pregnancy Categories C (first trimester) and D (second and third trimesters): See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

Array

Array

Array

Array


What are the side effects of Quinapril Hydrochloride and Hydrochlorothiazide?

Array

PRECAUTIONS

Array

Array

Postmarketing Experience

Array

Array

Array

Array

Array

Array

Array

Array

Array

Array

Array

Array

Array

Array

Clinical Laboratory Test Findings

Serum Electrolytes:

PRECAUTIONS

Creatinine, Blood Urea Nitrogen:

PRECAUTIONS

PBI and Tests of Parathyroid Function:

PRECAUTIONS

Hematology:

WARNINGS

Other

PRECAUTIONS

  Percent of Patients in Controlled Trials
  Quinapril/ HCTZ N = 943   Placebo N = 100
Headache 6.7 30
Dizziness 4.8 4
Coughing 3.2 2
Fatigue 2.9 3
Myalgia 2.4 5
Viral Infection 1.9 4
Rhinitis 2 3
Nausea and/or Vomiting 1.8 6
Abdominal Pain 1.7 4
Back Pain 1.5 2
Diarrhea 1.4 1
Upper Respiratory Infection 1.3 4
Insomnia 1.2 2
Somnolence 1.2 0
Bronchitis 1.2 1
Dyspepsia 1.2 2
Asthenia 1.1 1
Pharyngitis 1.1 2
Vasodilatation 1 1
Vertigo 1 2
Chest Pain 1 2
BODY AS A WHOLE: Asthenia, Malaise
CARDIOVASCULAR: Palpitation, Tachycardia,
  Myocardial Infarction, Cerebrovascular Accident,
  Hypertensive Crisis, Angina Pectoris, Orthostatic
  Hypotension, Cardiac Rhythm Disturbance
GASTROINTESTINAL: Mouth or Throat Dry,
  Pancreatitis, Abnormal Liver Function Tests
NERVOUS/PSYCHIATRIC: Nervousness, Vertigo,
RESPIRATORY: Sinusitis, Dyspnea
INTEGUMENTARY: Pruritus, Sweating Increased,
  Exfoliative Dermatitis, Photosensitivity Reaction, Alopecia,
  Pemphigus
UROGENITAL SYSTEM: Acute Renal Failure, Impotence
OTHER: Agranulocytosis, Thrombocytopenia, Arthralgia
Angioedema: Angioedema has been reported in 0.1% of patients receiving
  quinapril (0.1%) (see).
Fetal/Neonatal Morbidity and See Fetal/Neonatal
Mortality: Morbidity and Mortality
BODY AS A WHOLE: Weakness.
CARDIOVASCULAR: Orthostatic hypotension (may be potentiated by alcohol,
  barbiturates, or narcotics).
DIGESTIVE: Pancreatitis, jaundice (intrahepatic cholestatic), sialadenitis,
  vomiting, diarrhea, cramping, nausea, gastric irritation,
  constipation, and anorexia.
NEUROLOGIC: Vertigo, lightheadedness, transient blurred vision, headache,
  paresthesia, xanthopsia, weakness, and restlessness.
MUSCULOSKELETAL: Muscle spasm.
HEMATOLOGIC: Aplastic anemia, agranulocytosis, leukopenia,
  thrombocytopenia, and hemolytic anemia.
RENAL: Renal failure, renal dysfunction, interstitial nephritis
  (see ).
METABOLIC: Hyperglycemia, glycosuria, and hyperuricemia.
HYPERSENSITIVITY: Necrotizing angiitis, Stevens-Johnson syndrome,
  respiratory distress (including pneumonitis and
  pulmonary edema), purpura, urticaria, rash, and
  photosensitivity.



What should I look out for while using Quinapril Hydrochloride and Hydrochlorothiazide?

Anaphylactoid and Possibly Related Reactions:

Head and Neck Angioedema:

Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, emergency therapy including, but not limited to, subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) should be promptly administered

PRECAUTIONS

ADVERSE REACTIONS

Intestinal Angioedema:

Patients With a History of Angioedema:

CONTRAINDICATIONS

Anaphylactoid Reactions During Desensitization:

Anaphylactoid Reactions During Membrane Exposure:

Hepatic Failure:

Hypotension:

Impaired Renal Function:

Evaluation of the hypertensive patients should also include assessment of the renal function

DOSAGE AND ADMINISTRATION

Neutropenia/Agranulocytosis:

Fetal/Neonatal Morbidity and Mortality:

in utero

Impaired Hepatic Function:

Systemic Lupus Erythematosus:


What might happen if I take too much Quinapril Hydrochloride and Hydrochlorothiazide?


How should I store and handle Quinapril Hydrochloride and Hydrochlorothiazide?

Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). PROTECT FROM LIGHT. KEEP TIGHTLY CLOSED. Sarafem is a registered trademark of Eli Lilly and Company. 10 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      7414610 mg/12.5 mg tablets: NDC-54868-1802-020 mg/12.5 mg tablets: NDC 54868-2847-1  NDC 54868-2847-0 20 mg/25 mg tablets: NDC 54868-5475-0Dispense in tight containers as defined in the USP.Repackaging and Relabeling by:Physicians Total Care, Inc.Tulsa, OK      74146


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Mechanism of Action:

PRECAUTIONS

Pharmacokinetics and Metabolism:

DOSAGE AND ADMINISTRATION

Pharmacodynamics and Clinical Effects:

WARNINGS

Non-Clinical Toxicology
Anaphylactoid and Possibly Related Reactions:

Head and Neck Angioedema:

Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, emergency therapy including, but not limited to, subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) should be promptly administered

PRECAUTIONS

ADVERSE REACTIONS

Intestinal Angioedema:

Patients With a History of Angioedema:

CONTRAINDICATIONS

Anaphylactoid Reactions During Desensitization:

Anaphylactoid Reactions During Membrane Exposure:

Hepatic Failure:

Hypotension:

Impaired Renal Function:

Evaluation of the hypertensive patients should also include assessment of the renal function

DOSAGE AND ADMINISTRATION

Neutropenia/Agranulocytosis:

Fetal/Neonatal Morbidity and Mortality:

in utero

Impaired Hepatic Function:

Systemic Lupus Erythematosus:

Derangements of Serum Electrolytes:

Other Metabolic Disturbances:

Cough:

Surgery/Anesthesia:

Angioedema:

Pregnancy:

Symptomatic Hypotension:

Hyperkalemia:

Neutropenia:

NOTE:

Potassium Supplements and Potassium-Sparing Diuretics:

Lithium:

Tetracycline and Other Drugs That Interact with Magnesium:

Other Agents:

in vitro

in vitro

in vivo

in vitro

Salmonella typhimurium

in vivo

Drosophila

in vitro

Aspergillus nidulans

Pregnancy Categories C (first trimester) and D (second and third trimesters): See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

PRECAUTIONS

Postmarketing Experience

Clinical Laboratory Test Findings

Serum Electrolytes:

PRECAUTIONS

Creatinine, Blood Urea Nitrogen:

PRECAUTIONS

PBI and Tests of Parathyroid Function:

PRECAUTIONS

Hematology:

WARNINGS

Other

PRECAUTIONS

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).